Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?
01:32pm, Tuesday, 03'rd Jan 2023
Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Regeneron (REGN) Presents Positive Data on MM and FL Drugs
12:48pm, Tuesday, 13'th Dec 2022
Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.
Our 7 Top Biotech Stock Picks for 2023
05:42pm, Friday, 09'th Dec 2022
If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow,
Can These 2 Stocks Crush the Market Again in 2023?
09:37am, Sunday, 04'th Dec 2022
Both are riding the wave of major clinical wins
Stocks To Invest In Right Now? 3 Biotech Stocks To Watch
12:19pm, Friday, 02'nd Dec 2022
Is now a good time to add these biotech stocks to your watchlsit?
Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review
09:47am, Thursday, 01'st Dec 2022
The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript)
01:53pm, Wednesday, 30'th Nov 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 34th Annual Healthcare Conference Call November 30, 2022 8:00 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations
2 Market-Beating Stocks That Can Continue Rising in 2023
05:35am, Wednesday, 30'th Nov 2022
It's not too late to get in on the potential 2023 growth for these two stocks.
7 Undervalued Biotech Stocks to Buy Before They Boom
08:30pm, Tuesday, 29'th Nov 2022
You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript)
02:50pm, Tuesday, 29'th Nov 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 5th Annual Evercore ISI HealthCONx Conference November 29, 2022 11:45 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations John Lin
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
10:32am, Friday, 25'th Nov 2022
Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
Dexcom Leads 5 Stocks Near Buy Points
07:45am, Friday, 25'th Nov 2022
Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals. The post Dexcom Leads 5 Stocks Near Buy Points appeared first on Investor's Business Daily.
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
12:03pm, Wednesday, 23'rd Nov 2022
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma
02:08pm, Tuesday, 22'nd Nov 2022
Regeneron Pharmaceuticals, Inc. had a strong Q3 even if there are no longer sales of COVID therapy REGEN-Cov swelling the top line. The company's lead asset Eylea looks likely to face generic competit
